Sutro Biopharma, Inc.
STRO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001382101
No open-market purchases or sales by Sutro Biopharma, Inc. insiders were filed in the last 90 days; 100 institutions reported holding it in 13F filings for Q2 2026, worth $545.7M in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Sutro Biopharma, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 113
- −2 vs. Q2 2022
- Shares held
- 50.4M
- +4.30M (+9.3%) vs. Q2 2022
- Total value
- $279.6M
- +$38.7M (+16.0%) vs. Q2 2022
- New holders
- 10
- 49 more added
- Sold out
- 12
- 32 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting STRO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 100 | $545.7M |
| Q1 2026 | 78 | $358.3M |
| Q4 2025 | 63 | $64.8M |
| Q3 2025 | 88 | $46.4M |
| Q2 2025 | 101 | $39.6M |
| Q1 2025 | 113 | $40.0M |
| Q4 2024 | 123 | $117.6M |
| Q3 2024 | 130 | $216.4M |
| Q2 2024 | 119 | $185.1M |
| Q1 2024 | 117 | $301.7M |
| Q4 2023 | 114 | $238.7M |
| Q3 2023 | 109 | $194.3M |
| Q2 2023 | 120 | $251.6M |
| Q1 2023 | 116 | $247.5M |
| Q4 2022 | 119 | $403.7M |
| Q3 2022 | 113 | $279.6M |
| Q2 2022 | 115 | $240.9M |
| Q1 2022 | 114 | $342.2M |
| Q4 2021 | 117 | $593.2M |
| Q3 2021 | 120 | $752.5M |
| Q2 2021 | 124 | $766.7M |
| Q1 2021 | 138 | $1.01B |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Sutro Biopharma, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Rubric Capital Management LP | 1,400,000 | $7.77M | 0.39% | +500,000+55.6% | Added |
| Samsara BioCapital, LLC | 1,675,579 | $9.30M | 2.17% | 00.0% | Unchanged |
| Frazier Life Sciences Management, L.P. | 1,776,479 | $9.86M | 0.76% | 00.0% | Unchanged |
| Candriam Luxembourg S.C.A. | 1,798,838 | $9.98M | 0.07% | +1,736,225+2,772.9% | Added |
| Baillie Gifford & Co | 1,868,615 | $10.4M | 0.01% | +3,435+0.2% | Added |
| Vanguard Group Inc | 2,050,276 | $11.4M | 0.00% | +12,951+0.6% | Added |
| Millennium Management LLC | 2,537,070 | $14.1M | 0.02% | +230,278+10.0% | Added |
| Eventide Asset Management, LLC | 2,708,975 | $15.0M | 0.30% | 00.0% | Unchanged |
| Holocene Advisors, LP | 2,805,197 | $15.6M | 0.10% | 00.0% | Unchanged |
| BVF Inc | 3,447,946 | $19.1M | 0.79% | 00.0% | Unchanged |
| Franklin Resources Inc | 3,788,780 | $21.0M | 0.01% | +14,885+0.4% | Added |
| BlackRock Inc. | 4,008,370 | $22.2M | 0.00% | +285,745+7.7% | Added |
| Suvretta Capital Management, LLC | 5,020,000 | $27.9M | 1.17% | +375,000+8.1% | Added |
| Banco Santander, S.A. | 0 | $0 | 0.00% | −400,000−100.0% | Sold out |
| Graham Capital Management, L.P. | 0 | $0 | 0.00% | −251,921−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −162,006−100.0% | Sold out |
| Kennedy Capital Management, Inc. | 0 | $0 | 0.00% | −114,437−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −84,309−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −34,041−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −29,298−100.0% | Sold out |
| Point72 Hong Kong Ltd | 0 | $0 | 0.00% | −8,833−100.0% | Sold out |
| Skandinaviska Enskilda Banken AB (publ) | 0 | $0 | 0.00% | −5,100−100.0% | Sold out |
| Fairfield, Bush & Co. | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −120−100.0% | Sold out |
| Total Clarity Wealth Management, Inc. | 0 | $0 | 0.00% | −200−100.0% | Sold out |